Shanghai Fosun Pharmaceutical (Group) (2196) Fundamentals 2026 — P/E 18.2x, Revenue Analysis | SniperIQ

6.46 on the HKSE. This SniperIQ fundamentals page covers Shanghai Fosun Pharmaceutical (Group)'s valuation (P/E 18.2x, P/B 1.3x), profitability (net margin 8.2%), revenue (¥40.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Shanghai Fosun Pharmaceutical (Group)'s market cap?

Shanghai Fosun Pharmaceutical (Group) (2196) has a market capitalization of approximately HK$61.7B, trading at HK

6.46 on the HKSE. Market cap moves with the live share price.

What is Shanghai Fosun Pharmaceutical (Group)'s P/E ratio?

Shanghai Fosun Pharmaceutical (Group)'s trailing twelve-month P/E ratio is 18.2x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Shanghai Fosun Pharmaceutical (Group)?

Shanghai Fosun Pharmaceutical (Group) runs a net profit margin of 8.2%, a gross margin of 49.4%, and an operating margin of 9.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Shanghai Fosun Pharmaceutical (Group) generate?

Shanghai Fosun Pharmaceutical (Group) reported revenue of ¥40.4B for fiscal year 2025, with net income of ¥3.3B and earnings per share (EPS) of 1.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Shanghai Fosun Pharmaceutical (Group) pay a dividend?

Shanghai Fosun Pharmaceutical (Group) offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Shanghai Fosun Pharmaceutical (Group) financially healthy?

Shanghai Fosun Pharmaceutical (Group) carries a debt-to-equity ratio of 0.81x and a current ratio of 0.93x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Shanghai Fosun Pharmaceutical (Group) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Fosun Pharmaceutical (Group) (2196) the key facts are: market cap HK$61.7B, P/E 18.2x, revenue ¥40.4B, 52-week range 14.9-29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.